$AZN has released its latest earnings report, showcasing robust growth and developments. Total revenue surged 21% year-over-year, with a core EPS increase of 19%. While the company reported potential risks in China, ongoing investigations could impact their operations. Highlights include steady growth across various therapy areas and expectations of continued innovation. โ๏ธ๐ฐ Investors should note the evolving market conditions while anticipating future opportunities. For detailed insights, visit valueverge.com/AZN.